« Noted, Through Massive Self-Restraint, With Almost No Comment Whatsoever |
| Health Care Reform and the Drug Industry: How Goes It? »
February 16, 2011
The Key Player in the Sanofi-Genzyme Deal Speaks Out
In light of the two companies reaching an agreement on price yesterday afternoon, a behind-the-scenes participant in the deal asked people to remember what set the whole process in motion.
"If it weren't for me, this never would have gotten off the ground", claimed Vesivirus 2117. "Moving into that facility in Allston was the step that made it all possible", the virus claimed. "Does anyone think that Genzyme wouldn't just be humming along as before if it weren't for me? The stock price, the confidence of the shareholders - all that went down through my efforts, and I just want to make sure that credit is given where it's due".
The virus, which is not known to infect humans, pointed out that you don't have to directly invade the human body to affect human affairs. "Subtlety, that's the thing," the organism stated. "You come in through the front door - nose, mouth, whatever - with all your guns blazing, and sure, you get the press, the headlines. But right from the start, they're trying to bring you down. Now, infecting cell cultures, there's no immune system to worry about, and if they've never seen you before, well, no one knows you're there. Until you're really, really there, if you know what I mean."
The virus went on to say that its tenacity was just as crucial as its element of surprise. "They're been cleaning the place out for a year now", it said with satisfaction. "And are they sure that they've gotten rid of me? Is the FDA sure? I think not." Vesivirus 2117 said that it welcomed the chance to work with whoever Sanofi-Aventis assigned to its area. "Viruses, you know, we're international. Bonjour!"
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- A Last Summer Day Off
- The Early FDA
- Drug Repurposing
- The Smallest Drugs
- Life Is Too Short For Some Journal Feeds
- A New Look at Phenotypic Screening
- Small Molecules - Really, Really Small
- InterMune Bought